All In Biotech

Drug Trial Radar · NCT04947319

Study of Tirabrutinib (ONO-4059) in Patients With Primary Central Nervous System Lymphoma (PROSPECT Study)

An Open-label Phase II Study to Investigate the Efficacy, Safety, and Pharmacokinetics of Tirabrutinib in Patients With Primary Central Nervous System Lymphoma (PCNSL)

Last checked: Nov 20, 2026Latest source record: Mar 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

119

Actual

Start

Dec 29, 2021

Primary completion

Jan 27, 2026

Study completion Mar 31, 2027

Sponsor

Lead sponsor
Ono Pharmaceutical Co., Ltd.Industry
Sponsor type
Industry
First posted
Jul 1, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate the efficacy, safety, and pharmacokinetics of tirabrutinib monotherapy in patients with relapsed or refractory PCNSL (Part A), and tirabrutinib in combination with one of two different high dose methotrexate based regimens (methotrexate/ temozolomide/rituximab or rituximab/methotrexate/procarbazine/ vincristine) as first line therapy in patients with newly diagnosed, treatment naïve PCNSL (Part B)

Conditions

  • Refractory Primary Central Nervous System Lymphoma
  • Primary CNS Lymphoma

Interventions

  • TirabrutinibDrug

    Part A: Tirabrutinib 480 mg, taken orally, once a day on an empty stomach. Tirabrutinib treatment may be continued until disease progression or clinically unacceptable toxicity is observed.

  • TirabrutinibDrug

    Part B, Arm 1 - Tirabrutinib 320 mg or 480 mg, taken orally, once a day on an empty stomach in combination with an MTR induction regimen. Tirabrutinib with MTR treatment will be continued for 4 induction cycles (28-day/cycle), or until disease progression or clinically unacceptable toxicity is observed. For patients not receiving consolidation treatment following induction, tirabrutinib 480 mg will be continued until disease progression, unacceptable toxicities are observed, or the Investigator decides to stop treatment.

  • TirabrutinibDrug

    Part B, Arm 2 - Tirabrutinib 320 mg or 480 mg, taken orally, once a day on an empty stomach in combination with an R-MPV induction regimen. Tirabrutinib with R-MPV treatment will be continued for 4 induction cycles (28-day/cycle), or until disease progression or clinically unacceptable toxicity is observed. For patients not receiving consolidation treatment following induction, tirabrutinib 480 mg will be continued until disease progression, unacceptable toxicities are observed, or the Investigator decides to stop treatment.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall response rate (ORR) (Part A)Time frame: 1 year
  2. Tirabrutinib dose estimate (Part B)Time frame: 1 month
  3. Incidence and severity of adverse events (AEs) and serious adverse events (SAEs) during induction (Part B)Time frame: 4 months
  4. Complete response rate (CRR) (Part B)Time frame: 4 months

Locations

39 sites in 1 country. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham School of Medicine

    Birmingham, Alabama

  • Mayo Clinic- Phoenix

    Phoenix, Arizona

  • City of Hope Comprehensive Breast Cancer Center

    Duarte, California

  • University of California, Irvine

    Irvine, California

  • Stanford University

    Palo Alto, California

  • University of Colorado Denver

    Aurora, Colorado

  • Yale Cancer Center

    New Haven, Connecticut

  • Georgetown University, Lombardi Comprehensive Cancer Center

    Washington D.C., District of Columbia

  • Mayo Clinic- Jacksonville

    Jacksonville, Florida

  • University of Miami-Sylvester Cancer Center

    Miami, Florida

  • Orlando Health

    Orlando, Florida

  • Moffitt Cancer Center- Miami

    Pembroke Pines, Florida

  • Piedmont Healthcare

    Atlanta, Georgia

  • University of Kentucky

    Lexington, Kentucky

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts

  • Dana-Farber Cancer Institute - Brigham & Women's Hospital

    Boston, Massachusetts

  • University Of Michigan

    Ann Arbor, Michigan

  • Henry Ford Hospital

    Detroit, Michigan

  • The University of Kansas Cancer Center (KUCC) (Kansas City Cancer Center (KCCC)) - North

    Kansas City, Missouri

  • University of Nebraska Medical Center

    Omaha, Nebraska

  • Hackensack University Medical Center - John Theurer Cancer

    Hackensack, New Jersey

  • Roswell Park Comprehensive Cancer Center (RPCCC) (Roswell Park Cancer Institute (RPCI))

    Buffalo, New York

  • Memorial Sloan Kettering

    New York, New York

  • Columbia University Irving Medical Center

    New York, New York

  • Levine Cancer Center

    Charlotte, North Carolina

  • Duke University School of Medicine

    Durham, North Carolina

  • Cleveland Clinic

    Cleveland, Ohio

  • Providence Health Cancer Center

    Portland, Oregon

  • Penn State Hershey Cancer Center

    Hershey, Pennsylvania

  • Abramson Cancer Center University of Pennsylvania

    Philadelphia, Pennsylvania

  • Hillman Cancer Center, University of Pittsburgh

    Pittsburgh, Pennsylvania

  • Lifespan Rhode Island Hospital

    Providence, Rhode Island

  • Vanderbilt-Ingram Cancer Center

    Nashville, Tennessee

  • Houston Methodist Research Institute (HMRI)

    Houston, Texas

  • MD Anderson Cancer Center

    Houston, Texas

  • The University of Utah - Huntsman Cancer Institute (HCI)

    Salt Lake City, Utah

  • The University of Vermont - Fletcher Allen Health Care

    Burlington, Vermont

  • Seattle Cancer Care Alliance

    Seattle, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.